Laboratory evaluation of anti-heparin/PF4 antibody–positive patients
| Laboratory result . | Training set . | Validation set . |
|---|---|---|
| All patients, Confirm+ | 98/115 (85) | 77/97 (79) |
| All patients, Confirm− | 17/115 (15) | 20/97 (21) |
| HIT+ patients, Confirm+ | 71/74 (96) | 49/56 (88) |
| HIT+ patients, Confirm− | 3/74 (4) | 7/56 (12) |
| HIT− patients, Confirm+ | 27/41 (66) | 28/41 (68) |
| HIT− patients, Confirm− | 14/41 (34) | 13/41 (32) |
| Laboratory result . | Training set . | Validation set . |
|---|---|---|
| All patients, Confirm+ | 98/115 (85) | 77/97 (79) |
| All patients, Confirm− | 17/115 (15) | 20/97 (21) |
| HIT+ patients, Confirm+ | 71/74 (96) | 49/56 (88) |
| HIT+ patients, Confirm− | 3/74 (4) | 7/56 (12) |
| HIT− patients, Confirm+ | 27/41 (66) | 28/41 (68) |
| HIT− patients, Confirm− | 14/41 (34) | 13/41 (32) |
Values are n/N (%).
Patients were classified as HIT+ and HIT− on the basis of clinical grounds, as described in “Definition of clinical HIT status.”